AdAlta’s Funding Milestone Ends Meurs Agreement but Raises Dilution Questions
AdAlta Limited has completed the final share issuance under its Investment Agreement with the Meurs Group, securing the full $700,000 investment that bolstered its cellular immunotherapy development.
- Final tranche of shares issued to Meurs Group completes $700K investment
- Investment provided critical liquidity for AdAlta’s ‘East to West’ strategy
- No further shares to be issued under the Meurs Investment Agreement
- AdAlta positioned to raise private capital for advancing CAR-T therapies
- Share issuance approved previously by shareholders at 2024 EGM
Completion of Meurs Investment Agreement
AdAlta Limited (ASX, 1AD), a clinical-stage biotech focused on cellular immunotherapies for solid cancers, has announced the final issuance of shares under its Investment Agreement with the Meurs Group. This long-standing shareholder had committed to invest up to $700,000, with the last $363,000 worth of shares issued on 28 October 2025. This issuance completes the full settlement of the subscription amount, marking the end of share obligations under the agreement.
Strategic Support at a Critical Juncture
The Meurs Group’s investment, initiated in April 2024, provided AdAlta with vital working capital during the early phases of developing its innovative ‘East to West’ cellular immunotherapy strategy. This approach integrates Asia’s advanced T cell therapy innovations with Australia’s clinical and manufacturing capabilities, aiming to bring cutting-edge CAR-T therapies to patients with solid tumors, a segment that remains largely underserved.
AdAlta’s CEO, Tim Oldham, expressed gratitude for the Meurs Group’s support, highlighting how the investment offered strategic flexibility at a pivotal time. With the Meurs Investment Agreement now fully settled, AdAlta is positioned to pursue further private capital raises to accelerate the development and commercialization of its CAR-T technologies globally.
Financial and Shareholder Context
The shares issued in this final tranche were priced at $0.0018 each, consistent with terms disclosed in the initial 2024 announcement. The issuance of over 201 million shares was previously approved by shareholders at an Extraordinary General Meeting in July 2024, ensuring transparency and alignment with governance standards.
Completing this investment agreement removes a layer of uncertainty from AdAlta’s capital structure, allowing the company to focus on advancing its pipeline, including its first-in-class fusion protein AD-214, which targets fibrotic diseases and is available for partnering.
Looking Ahead
With the Meurs Group’s commitment fully realized, AdAlta’s next chapter involves securing additional funding to support clinical trials and manufacturing scale-up. The company’s disciplined, capital-efficient model aims to deliver rapid returns on investment across multiple T cell therapy projects, positioning it to capitalize on the growing cellular immunotherapy market, projected to reach over US$20 billion by 2028.
Bottom Line?
AdAlta closes a key funding chapter with Meurs Group, setting the stage for fresh capital to fuel its CAR-T ambitions.
Questions in the middle?
- What are the timelines and targets for AdAlta’s upcoming private capital raises?
- How will the new share issuance impact existing shareholders in terms of dilution?
- What progress can investors expect soon on AdAlta’s ‘East to West’ cellular immunotherapy pipeline?
